Monoclonal Antibodies Market Forecasts to 2030 - Global Analysis By Source Type (Humanized, Chimeric, Murine, Human and Other Source Types), Production Type, Indication, Route of Administration, Distribution Channel, Application, End User and By Geography
Estimated Year Value (2023)
US $230.6 BN
Projected Year Value (2030)
US $591.5 BN
CAGR (2023 - 2030)
North America, Europe, Asia Pacific, South America, and Middle East & Africa
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa
Highest Growing Market
According to Stratistics MRC, the Global Monoclonal Antibodies Market is accounted for $230.6 billion in 2023 and is expected to reach $591.5 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Monoclonal antibodies (mAbs) are a class of proteins with the capacity to attach to particular cell types. These are identical immunoglobulins that recognise a specific binding site on the antigen and were produced by a single B-cell. MAbs are being utilised more frequently for therapeutic and diagnostic purposes for various diseases because of their selectivity to distinct epitopes. Monoclonal antibodies are now widely used to treat a variety of conditions, including cancer, cardiovascular illness, autoimmune disorders, blood disorders, and infectious diseases.
According to the World Health Organization, in 2020, around 10 million people died due to cancer worldwide. This has proportionated one third deaths due to cancer in respective year.
Favourability for personalised medicine has increased
The desire for personalised medicine is increasing as research and development of therapeutic antibodies has paved the way for targeted therapies because different people respond and behave differently to a given medication. Since monoclonal antibodies are used in cancer therapy, these treatments are less likely to cause adverse effects than traditional chemotherapy. The development of the market is anticipated to be aided by personalised cancer therapy and fewer adverse effects from monoclonal antibodies.
Stringent regulatory issues
The market's expansion is hindered by strict regulatory requirements pertaining to drug approvals and drug testing. Additionally, a number of nations prohibit the testing of medicines on people before they have received the required authorisation. The ability of commercially available treatments to cure once-incurable diseases has paved the path for the introduction of ground-breaking drugs to the market. The market's expansion is hampered by the numerous regulatory compliances that are associated with these medications.
Increase in the incidence of cancer
One of the main factors influencing the market's growth rate is the rising incidence of cancer. Due to the rapidly expanding global market for monoclonal antibodies, monoclonal antibodies are increasingly being employed in the treatment of numerous tumours in industrialised nations. Rapid increases in the prevalence of rare and chronic infectious diseases, as well as the large number of monoclonal antibodies recommended for use in cancer treatment regimens, have provided the market with potential for revenue growth.
High cost associated with monoclonal antibodies
Monoclonal antibodies are still only employed in industrialised nations and not in emerging or poor nations due to the high cost of production. Such high drug costs can impede uptake and restrict access to medicines for sizable patient populations in poor nations. The high expenditures of the development and the subsequent price increase may limit market expansion.
The pandemic had three main effects on the economy: it directly influenced drug demand and production, it disrupted distribution systems, and it had a financial impact on businesses and financial markets. The market for monoclonal antibodies has benefited from the impact since these antibodies work to prevent and treat early infections. Monoclonal antibodies are being used by numerous businesses in an effort to develop an effective vaccine for a novel corona virus disease. The researchers are assisted by government agencies by their approval of crises.
The cancer segment is expected to be the largest during the forecast period
The cancer segment is expected to be the largest during the forecast period, owing to increased prevalence of cancer. This expansion is simply ascribed to the increased demand for monoclonal antibodies in the treatment of various cancers. One of the main reasons why there is such a large demand for monoclonal antibodies among cancer patients is their increased effectiveness in the treatment of cancer with minimal or no adverse effects.
The hospital pharmacy segment is expected to have the highest CAGR during the forecast period
The hospital pharmacy segment is expected to have the highest CAGR during the forecast period. This is due to a rise in hospital admissions brought on by the rising prevalence of a number of chronic diseases like cancer, autoimmune disorders, and rheumatoid arthritis. The market income of hospital pharmacy has increased as a result of greater access to modern healthcare services. These pharmacies are an easy way to purchase a variety of medications due to the large variety of products and drugs they carry.
Region with largest share:
North America is projected to hold the largest market share during the forecast period, owing to the strong presence of key business players and number of product approvals. Demand for monoclonal antibodies in the local market is driven by increased product acceptance for efficient disease treatment. In addition, rising R&D spending by businesses and government funding for cancer research have facilitated the development of innovative monoclonal antibody treatments.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the increasing disposable income and rising focus on healthcare. The main causes that are anticipated to increase the prevalence of cancer and other chronic diseases in the population are the rising consumption of processed foods, rising smoking rates, and rising tobacco use. Additionally, the growing elderly population will have a favourable effect on sales in the near future.
Key players in the market
Some of the key players in Monoclonal Antibodies market include Johnson & Johnson Services, Inc., Viatris Inc., Abbott Laboratories, Eli Lilly And Company, Bristol-Myers Squibb, Biogen Inc., Merck & Co., Inc., Pfizer Inc, Novartis AG, Thermo Fisher Scientific, Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG and Lonza Group.
In March 2022, Sanofi S.A. and Blackstone Life Sciences entered a collaboration for accelerating the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.
In February 2022, Bebtelovimab is an antibody that can reduce the effects of Omicron variant. Eli Lilly and Company announced that the Food and Drug Administration (FDA) of the United States had given bebtelovimab an Emergency Use Authorization (EUA).
In January 2022, Lonza and HaemaLogiX Ltd. (HaemaLogiX) made a deal for Lonza to make the next clinical batch (cGMP) of KappaMab, HaemaLogiX's most important treatment candidate for multiple myeloma.
Source types Covered:
• Other Source Types
Production Types Covered:
• In Vitro
• In Vivo
Route of Administration Covered:
Distribution Channels Covered:
• Other End Users
• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy
End Users Covered:
• Specialty Centers
• Research Institutes
• Other End Users
• North America
o Rest of Europe
• Asia Pacific
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
3 Market Trend Analysis
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Monoclonal Antibodies Market, By Source Type
5.6 Other Source Types
6 Global Monoclonal Antibodies Market, By Production Type
6.2 In Vitro
6.3 In Vivo
7 Global Monoclonal Antibodies Market, By Indication
7.2 Infectious Diseases
7.3 Inflammatory Diseases
7.4.1 Lung cancer
7.4.2 Colorectal cancer
7.4.3 Ovarian cancer
7.4.4 Breast cancer
7.5 Autoimmune Diseases
7.6 Other Indications
8 Global Monoclonal Antibodies Market, By Route of Administration
9 Global Monoclonal Antibodies Market, By Distribution Channel
9.2 Online Pharmacy
9.3 Hospital Pharmacy
9.4 Retail Pharmacy
10 Global Monoclonal Antibodies Market, By Application
10.2 Infectious Diseases
10.3 Neurological Diseases
10.4 Autoimmune Diseases
10.6 Other Applications
11 Global Monoclonal Antibodies Market, By End User
11.2 Specialty Centers
11.4 Research Institutes
11.5 Other End Users
12 Global Monoclonal Antibodies Market, By Geography
12.2 North America
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 Key Developments
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.5 Other Key Strategies
14 Company Profiling
14.1 Johnson & Johnson Services, Inc.
14.2 Viatris Inc.
14.3 Abbott Laboratories
14.4 Eli Lilly And Company
14.5 Bristol-Myers Squibb
14.6 Biogen Inc.
14.7 Merck & Co., Inc.
14.8 Pfizer Inc
14.9 Novartis AG
14.10 Thermo Fisher Scientific, Inc.
14.11 AstraZeneca plc
14.12 GlaxoSmithKline plc
14.13 Novo Nordisk A/S
14.14 Sanofi S.A.
14.15 Merck & Co., Inc.
14.16 Amgen Inc.
14.17 Bayer AG
14.18 Lonza Group
List of Tables
1 Global Monoclonal Antibodies Market Outlook, By Region (2021-2030) ($MN)
2 Global Monoclonal Antibodies Market Outlook, By Source Type (2021-2030) ($MN)
3 Global Monoclonal Antibodies Market Outlook, By Humanized (2021-2030) ($MN)
4 Global Monoclonal Antibodies Market Outlook, By Chimeric (2021-2030) ($MN)
5 Global Monoclonal Antibodies Market Outlook, By Murine (2021-2030) ($MN)
6 Global Monoclonal Antibodies Market Outlook, By Human (2021-2030) ($MN)
7 Global Monoclonal Antibodies Market Outlook, By Other Source Types (2021-2030) ($MN)
8 Global Monoclonal Antibodies Market Outlook, By Production Type (2021-2030) ($MN)
9 Global Monoclonal Antibodies Market Outlook, By In Vitro (2021-2030) ($MN)
10 Global Monoclonal Antibodies Market Outlook, By In Vivo (2021-2030) ($MN)
11 Global Monoclonal Antibodies Market Outlook, By Indication (2021-2030) ($MN)
12 Global Monoclonal Antibodies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
13 Global Monoclonal Antibodies Market Outlook, By Inflammatory Diseases (2021-2030) ($MN)
14 Global Monoclonal Antibodies Market Outlook, By Cancer (2021-2030) ($MN)
15 Global Monoclonal Antibodies Market Outlook, By Lung cancer (2021-2030) ($MN)
16 Global Monoclonal Antibodies Market Outlook, By Colorectal cancer (2021-2030) ($MN)
17 Global Monoclonal Antibodies Market Outlook, By Ovarian cancer (2021-2030) ($MN)
18 Global Monoclonal Antibodies Market Outlook, By Breast cancer (2021-2030) ($MN)
19 Global Monoclonal Antibodies Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
20 Global Monoclonal Antibodies Market Outlook, By Other Indications (2021-2030) ($MN)
21 Global Monoclonal Antibodies Market Outlook, By Route of Administration (2021-2030) ($MN)
22 Global Monoclonal Antibodies Market Outlook, By Intravitreal (2021-2030) ($MN)
23 Global Monoclonal Antibodies Market Outlook, By Subcutaneous (2021-2030) ($MN)
24 Global Monoclonal Antibodies Market Outlook, By Intravenous (2021-2030) ($MN)
25 Global Monoclonal Antibodies Market Outlook, By Distribution Channel (2021-2030) ($MN)
26 Global Monoclonal Antibodies Market Outlook, By Online Pharmacy (2021-2030) ($MN)
27 Global Monoclonal Antibodies Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
28 Global Monoclonal Antibodies Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
29 Global Monoclonal Antibodies Market Outlook, By Application (2021-2030) ($MN)
30 Global Monoclonal Antibodies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
31 Global Monoclonal Antibodies Market Outlook, By Neurological Diseases (2021-2030) ($MN)
32 Global Monoclonal Antibodies Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
33 Global Monoclonal Antibodies Market Outlook, By Oncology (2021-2030) ($MN)
34 Global Monoclonal Antibodies Market Outlook, By Other Applications (2021-2030) ($MN)
35 Global Monoclonal Antibodies Market Outlook, By End User (2021-2030) ($MN)
36 Global Monoclonal Antibodies Market Outlook, By Specialty Centers (2021-2030) ($MN)
37 Global Monoclonal Antibodies Market Outlook, By Hospitals (2021-2030) ($MN)
38 Global Monoclonal Antibodies Market Outlook, By Research Institutes (2021-2030) ($MN)
39 Global Monoclonal Antibodies Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at email@example.com
Frequently Asked Questions
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: firstname.lastname@example.org or phone: +1-301-202-5929
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at email@example.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.